Clinical-stage biopharmaceutical company DBV Technologies (Euronext Paris:DBV) (Nasdaq Capital Market:DBVT) on Friday announced a financing agreement of up to USD306.9m (EUR284.5m), including USD125.5m (EUR116.3m) upfront and up to USD181.4m (EUR168.2m) contingent on the full exercise of warrants.
These funds will support the preparation and submission of a Biologics License Application (BLA) for the Viaskin peanut patch, for the treatment of peanut allergy in children aged 4 to 7, and its potential US commercial launch. The financing will result in an immediate dilution of 22.4%, rising to 73.7% if all warrants are exercised.
The financing was led by MPM BioImpact, Adage Capital Management LP, Janus Henderson Investors, Vivo Capital and other healthcare-focused funds.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne